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OBJECTIVE—To evaluate the frequency of normalization, the persistence of remission, and
the impact on normalization of glycemic control and lipid proﬁle, we analyzed data from a
retrospective observational cohort study of type 1 diabetic children and adolescents with abnor-
mal urinary albumin excretion (UAE).
RESEARCH DESIGN AND METHODS—All diabetic children and adolescents (n = 41)
who had persistent abnormal UAE in the period of 1984 to 2008 and followed up until 2009
(follow-up duration = 13.1 6 6.2 years) were included in the study. Nine patients progressed to
macroalbuminuria; 24 patients were administered ACE inhibitor treatment.
RESULTS—The cumulative prevalence of abnormal UAE was 9%. During follow-up, 14 of 17
untreated and 19 of 24 treated patients reverted to normoalbuminuria. In the remission group
compared with the nonremission group, A1C levels during follow-up decreased (7.5 6 1.0 vs.
9.4 6 1.2%, P , 0.0001) and serum HDL cholesterol increased (52.7 6 11.3 vs. 42.7 6 8.6
mg/dL, P , 0.05). The micro-macroalbuminuric patients had lower HDL cholesterol (51.0 6
11.4 vs. 62.4 6 13.6 mg/dL, P , 0.0001) than 134 normoalbuminuric diabetic patients.
CONCLUSIONS—Microalbuminuria and macroalbuminuria were not permanent in most of
our diabetic children and adolescents. If abnormal UAE values are high and persist for .1y e a r ,
only long-lasting treatment with ACE inhibitors seems able to induce persistent remission,
especially when associated with good metabolic control and high HDL cholesterol levels.
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I
n the early 1980s, it was widely ac-
cepted that microalbuminuria (MA)
inexorably predicted progressive ne-
phropathy(1,2).Inthe1990s,threestud-
ies on pediatric patients (3–5) challenged
the predictive value of MA for renal dis-
ease.Severalfurtherstudiesinadultscon-
ﬁrmed that MA may be transient so that
now MA is considered a surrogate marker
forunderlyingrenalstructuraldamage(6)
and a lessprecise predictor of diabetic ne-
phropathy risk than described originally.
In fact, ,20% of patients (7,8) with type
1 diabetes and MA progressed to overt
nephropathy, whereas approximately
50–60% reverted to normal (7,8). Fur-
thermore, it is noteworthy that approxi-
mately one-third of the patients with
.50 years of diabetes (the Golden
Years Cohort), despite showing MA or
macroalbuminuria, were not affected by
renal deterioration (9). It is well known
that the chances of reversal to normoal-
buminuria are increased by blockers of
the renin-angiotensin system (6,10,11),
despite the fact that others denied that
assumption(7).Ithas recently been dem-
onstrated that the blockade of the renin-
angiotensin system is not effective in
primary prevention of diabetic nephrop-
athy (12). Furthermore, there is little ev-
idence on the effectiveness of ACE
inhibitors within the pediatric popula-
tion, and in the few studies published,
the sample size was small and the follow-
up was short (13,14).
The present longitudinal non-
randomized study presents the long-
term outcome of our diabetic children
and adolescents who in the last 25 years
developed MA and were treated or not
treated with ACE inhibitors in an un-
controlledway.Thepreliminaryresultsof
this cohort of patients were published in
1990 (15).
The aimsofthe studywereasfollows:
1) to study the percentage of patients re-
verting from MA to normoalbuminuria
with and without therapy; 2)t oo b s e r v e
the persistence with time of normaliza-
tion; and 3)to calculate the abilityofmet-
abolic control and lipid proﬁle to predict
the risk of nephropathy.
RESEARCH DESIGN AND
METHODS—From 1984 to 2008, all
diabetic patients (n = 490) followed up in
our center underwent repeated evalua-
tions of daily urinary albumin excretion
(UAE) (15). Forty-four patients (9%)
were identiﬁed as having abnormal UAE
on the basis of two or all three 24-h urine
collections .30 mg/day according to the
International Society for Pediatric and
Adolescent Diabetes criteria (16), with
no urinary tract infection. Only the
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Pathophysiology/Complications
ORIGINAL ARTICLEpatients (41/44 [93%]; 20 male and 21
female) with a follow-up to 2009 were in-
cluded in the study. The age at onset of
diabetes was8.6 63.6 years (range1.33–
14.25). At ﬁrst abnormal UAE detection,
age was 12.9 6 3.8 years (range 4.8–
23.3), 12 patients were prepubertal, 22
patients were pubescent, and 7 patients
were pubertal; the duration of diabetes
was 4.2 6 4.7 years (range 0–16.7).
Mean duration of follow-up from MA on-
set was 13.1 6 6.2 years (range 1.5–
24.8). Only 5% were followed up for
,5 years and 41% had .15 years of
follow-up. A total of 134 diabetic patients
matched for age with normal UAE were
used as controls to evaluate lipid param-
eters. In the control group, 15% were
overweight (BMI .75th percentile) and
1% were obese (BMI .95th percentile),
whereas in the 41 patients with abnormal
UAE, at the time of ﬁrst detection, 12%
were overweight and 5% were obese. The
difference was not statistically signiﬁcant.
ACE inhibitors (enalapril) were adminis-
tered to 24 of 41 patients (59%) for some
period of time, whereas 17 patients were
never treated. Therapy started at a mean
age of 15.5 6 4.5 years (minimum 8.8
years) and lasted for 6.0 6 4.3 years.
The choice of the patients to be treated
was inﬂuenced by the time MA was dis-
covered. Between 1984 and 1989, we did
not treat any patients because there was
insufﬁcient evidence in the literature in
regardtotheefﬁcacyandsafetyoftherapy
in normotensive diabetic patients with
MA; from 1990 to 1995, after new data
reporting favorable results of ACE inhib-
itor use were published (10), we treated
a l lp a t i e n t sw i t ha b n o r m a lU A E ;s i n c e
1996, because of new data indicating a
spontaneous normalization of MA (3,4),
which took place, according to our data
(5), after the end of puberty, we treated
onlyselectedpatientswithMA.Theselec-
tion criteria were the presence of macro-
albuminuria or persistence of values of
UAE .100 mg/day for .12 months in
pubescent patients and for .6m o n t h s
in postpubertal patients. The initial dose
was 10 mg once per day in the morning
forallpatientsandwasdecreasedto5mg/
day because of the appearance of side ef-
fects in seven patients (hypotension;
cough in one patient) and increased
after a mean period of 4.8 6 2.6 years to
20 mg/day because of lack of UAE value
improvement (increase or decrease of
,10%oftheinitialvalue)inﬁvepatients.
When UAE values remained normal for
.18 months, therapy was stopped.
Methods
UAE was evaluated every 3–12 months in
all patients. Each patient was trained on
the two separate urine collections of the
daytime (h 8–20) and night-time (h 20–
8). Albuminuria was determined by ra-
dioimmunoassay with double antibody
(Sclavo, Milan, Italy). The upper limit of
thenormalrangewas30mg/day(15).MA
was deﬁned as the presence of UAE be-
tween 30 and 300 mg/24 h in two or all
three 24-h urine samples over a period of
3–6 months (16), with no urinary tract
infection, and macroalbuminuria as the
presence of UAE .300 mg/day. Urine
culturewasperformedinallpatients.Cre-
atinine was evaluated once per year with
theJaffè method.Glomerularﬁltrationrate
(GFR) was calculated with the Schwartz
and Counahan-Barratt methods until age
18 years and with the estimated Modiﬁ-
cation of Diet in Renal Disease (MDRD)
afterward. Because the values obtained in
the transition phase by means of the two
methods were statistically different (P ,
0.0001), the analysis of the possible GFR
variations was performed separately by
comparing the ﬁrst and last value of each
time period (,18 years/.18 years). BMI
wasexpressedaccordingtotheItalianper-
centiles for age and sex. HbA1c levels were
measured by HPLC with the Auto A1c
TM Analyzer HA 8110 (Kyoto Daiichi,
Kagaku, Japan). The normal range was
4.3–5.9%. Serum cholesterol, HDL cho-
lesterol, and triglycerides were measured
with standard laboratory techniques;
LDL cholesterol was calculated with the
Friedewald equation. Detailed Tanner
staging of puberty was available in all pa-
tients. Arterial blood pressure was mea-
sured with the patients seated using a
standard mercury sphygmomanometer at
each examination and calculated as the
mean of 2 measurements. Patients with a
blood pressure .95th percentile for age
were considered hypertensive (17).
Statistical analysis
In each patient with abnormal UAE val-
ues, in addition to the ﬁrst abnormal
value, all measurements performed dur-
ing the entire follow-up of pathologic
UAE values were used to calculate mean
UAE values. The remaining parameters,
HbA1c and lipid proﬁles, were evaluated
both at the onset of abnormal UAE and
during the whole abnormal UAE period
or the possible subsequent normalization
period. All calculations were performed
with the commercially available program
SPSS 14.0.1 (Statistical Package for Social
Science, Chicago, IL). Data distribution
was analyzed by means of skewness and
kurtosis coefﬁcients and Kolmogorov–
Smirnovtest.Innormallydistributed var-
iables, comparison between groups was
performed by unpaired Student t test,
and comparison within groups was per-
formed by a paired t test. Pearson corre-
lation coefﬁcients were used to calculate
correlations between normally distrib-
uted values. In non-normally distributed
variables, a Mann–Whitney U test, a
Wilcoxon test, and Spearman rank corre-
lation coefﬁcients were used. Categoric
variables were analyzed using a x
2 test.
P , 0.05 was considered as signiﬁcant
for each test.
RESULTS—Of the 490 patients fol-
lowed up, 44 were identiﬁed as having
MA, and 10 (23%) of these progressed to
macroalbuminuria. Therefore, the cumu-
lative prevalence of abnormal UAE was
9% (95% CI 6.5–11.5): 7% (34 patients)
with MA and 2% (10 patients) with mac-
roalbuminuria. Of the 41 patients with
MA included in the study, 9 progressed
to macroalbuminuria (Fig. 1) after 1–3.5
yearsofMA.No patients with macroalbu-
minuria were overweight.
Eight of these 41 patients showed
abnormal UAE values since diabetic on-
set. These eight patients were all pubes-
cent and showed an older age at onset
(12.4 6 1.4 vs. 7.7 6 3.4 years, P ,
0.0001) than the patients with later onset
of MA (5.2 6 4.7 years after diabetes di-
agnosis).
During follow-up, 14 of 17 patients
(82%) who had never received ACE in-
hibitors went into spontaneous remis-
sion; the duration of abnormal UAE had
been 2.1 6 1.7 years, and the remission
was sustained for 9.6 6 6.3 years (Table
1). In the remaining three untreated pa-
tients, one remained with MA and two
progressed to macroalbuminuria, al-
though one of these two patients then re-
gressed to MA (Fig. 1). Of the 24 patients
who were treated with ACE inhibitors, 19
achieved normal UAE levels on treatment
(79%); 11 of these 19 patients stopped
therapy according to the protocol, and
all were able to maintain normal levels
even after medication withdrawal. Main-
tenanceofnormallevelsofftreatmentwas
achievable in 9 of 17 patients who had
onlyMAwhenACEinhibitorswerestarted
and in two of the seven patients who pre-
sented macroalbuminuria when ACE in-
hibitors were started. In those achieving
normal levels off treatment who had only
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Salardi and AssociatesMA, ACE inhibitor treatment was carried
out for a mean of 2.4 6 1.1 years, and the
remission off treatment has lasted for
11.3 6 5.3 years. In those achieving nor-
mal levels off treatment who had macro-
albuminuria, ACE inhibitor treatment
was carried out for a mean of 7.7 6 2.3
years and the remission off treatment has
lasted for 9.0 6 3.9 years. Of the 18 pa-
tients with only daytime abnormal UAE
values, 11 did not receive ACE inhibitors
and 10 spontaneously regressed to nor-
moalbuminuria. No patients with only
daytime abnormal UAE values developed
macroalbuminuria.
Arterial blood pressure was elevated
in eight patients: persistently in two pa-
tients(onemacroalbuminuricpatientand
one microalbuminuric patient) and ﬂuctu-
ating in six patients (two macroalbumin-
uric patients and four microalbuminuric
patients). Thedistributionofhypertensive
patients was not different between the
groupswithMAormacroalbuminuriaand
between normalized and non-normalized
patients.
Creatinine values remained within
the normal range (,1.20 mg/dL) in all
patientsthroughoutfollow-up.Estimated
GFR mean values were not statistically
different between start and end of both
pediatric and adult periods. However, in
two patients who had developed macro-
albuminuria (the ﬁrst untreated and the
second treated and improved from mac-
roalbuminuria to MA), we found a pro-
gressivelossofﬁltrationfunctionupto79
and 62 mL/min/1.73 m
2, respectively.
In the remission group compared
with the nonremission group, mean
UAE values during the whole abnormal
UAE period were lower (137.0 6 107.5
vs. 286.7 6 142.8 mg/24 h; P = 0.002),
HbA1c levels during the whole follow-up
period decreased (7.5 6 1.0 vs. 9.4 6
1.2%; P , 0.0001), and serum HDL cho-
lesterol at ﬁrst abnormal UAE detection
washigher(P=0.04)(Table2).HDLcho-
lesterol levels after treatment with ACE
inhibitors compared with levels at entry
were higher (P , 0.001 paired t test in
the 21 patients with available data) in 18
normalized patients and 3 patients with
levels of abnormal, although decreased,
UAE values. Furthermore, lower HDL
cholesterol levels and higher LDL cho-
lesterol levels characterized the whole
group of micro-macroalbuminuric pa-
tients compared with the control group
of normoalbuminuric diabetic patients
(P , 0.0001 and P = 0.004, respectively)
(Table 2). In the micro-macroalbuminuric
g r o u p ,9o f4 1p a t i e n t s( 2 2 % )s h o w e d
lower HDL cholesterol levels than cut
point by age/sex of the general population
(18), whereas in the control group of
Table 1—Clinical and laboratory data in 41 diabetic children and adolescents with abnormal UAE, showing values in the whole group
of patients and in those with MA or macroalbuminuria, treated or untreated
All patients (n =4 1 )
Microalbuminuric
patients (n =3 2 )
Macroalbuminuric
patients (n =9 ) U n t r e a t e d( n = 17) Treated (n =2 4 )
Mean UAE values during the
whole abnormal UAE
period (mg/24 h) 166.2 6 127.9 114.9 6 59.4* 356.9 6 124.5 157.7 6 122.7 187.3 6 134.7
HbA1c during the whole
abnormal UAE period (%) 7.8 6 1.3 7.7 6 1.3 8.1 6 1.3 7.6 6 1.5 8.0 6 1.3
Duration of abnormal UAE
before the normalization
(years) 5.6 6 4.6 (n = 33) 4.7 6 4.4† (n =2 7 ) 1 0 . 36 2.5 (n =6 ) 2 . 16 1.7* (n =1 4 ) 8 . 76 4.2 (n = 19)
Duration of normalization
after abnormal UAE
(years) 8.1 6 5.9 (n = 33) 8.3 6 5.9 (n = 27) 5.3 6 4.5 (n =6 ) 9 . 66 6.3 (n =1 4 ) 6 . 86 5.8 (n = 19)
Duration of therapy before
the normalization (years) — 4.6 6 3.7‡ (n = 13) 9.2 6 2.6 (n =6 ) — 6.0 6 3.8 (n = 19)
Duration of therapy before
stop therapy (years) — 2.4 6 1.1* (n =9 ) 7 . 76 2.3 (n =2 ) — 3.4 6 2.5 (n = 11)
Duration of remission off
treatment (years) — 11.3 6 5.3 (n =9 ) 9 . 06 3.9 (n =2 ) — 10.9 6 5.0 (n = 11)
*P , 0.0001; †P , 0.01; ‡P , 0.025 vs. the respective group.
Figure 1—Patient ﬂowchart (N, nighttime MA; D, only daytime MA).
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Lipids and microalbuminuria in youth with diabetesnormoalbuminuricpatients,theseabnor-
mal values were found in 5.2% of the pa-
tients (7/134) (x
2 =8 . 6 6 ,P =0 . 0 0 3 ) .T h e
percentage of overweight patients was
not different between those with normal
HDL values and those with low HDL val-
ues. Moreover, we observed a positive
relationship between UAE levels and
HbA1c (P = 0.03) and triglycerides (P =
0.024), and a negative correlation with
HDL cholesterol levels (P = 0.017). HDL
cholesterol values were not correlated
with BMIor HbA1c. Total cholesterol val-
u e sm e a s u r e di nt h ew h o l ep e r i o dw e r e
highly signiﬁcantly correlated (P ,
0.0001) with both triglycerides (r =
0.62) and LDL cholesterol (r =0 . 6 9 ) ,
whereas they were never correlated with
HDL cholesterol (r =0 . 0 9 ,P =n o ts i g n i f -
icant).
CONCLUSIONS—Ourresultsshowed
that in an unselected cohort of young
patients with type 1 diabetes and abnor-
malUAE,revertingtonormalisnotarare
event in untreated patients (82%) and
ACE inhibitor–treated patients (79%).
The explanation for the similar percent-
age in the two groups depends mainly
on the fact that since 1996 we treated the
patients who were more severely affected,
selected because they showed high UAE
levels (.100 mg/day) and had not spon-
taneously regressed after .1 year. It is
difﬁcult to compare our data with other
published data, reporting normalization
in 50–60% of adults, because many
variables were not considered homo-
geneously in the various studies. For
example, the method of collecting urine
samples (24 h or morning sample) was
not uniform, which may inﬂuence the
deﬁnition of abnormal UAE. If we had
used only the morning sample, we
would not have included and labeled as
microalbuminuric a signiﬁcant num-
ber of patients (18). Also, the duration
of follow-up was different, and this is
fundamental to establish the exact
number of regressors. Finally, transient
cases (i.e., with MA disappearing within
1 year) were included in some studies
(19). Despite the reported differences, it
has long been known that MA can fre-
quently normalize in adolescents, and as
early as 1996 Rudberg and Dahlquist (4)
reported that only 35% of patients pro-
gressed during a 3-year follow-up. How-
ever, our study may contain some bias to
justify the high percentage of normaliza-
tions compared with the literature, that is,
the inclusion of near-normal patients,
with low-grade abnormal UAE, present
only during daytime, and of short dura-
tion, or the inclusion of pubertal patients.
During this period, important hormonal
changes could act as an “exercise test” for
the kidneys of predisposed patients,
which would be temporary and would
ﬁnish at the end of puberty by itself (5).
Supporting this hypothesis is the fact that
in many of our patients in whom diabetes
started at mid-puberty, MA was already
present at the diagnosis of diabetes. On
the other hand, if this bias exists when
considering the whole group of patients,
the same confounding factors cannot be
advocated when dealing with the most
pathologiccases,thatis,thosewithpersis-
tent nocturnal high-grade abnormal UAE
and those with macroalbuminuria, in
whom a high percentage of remissions is
conﬁrmed. In our patients with mac-
roalbuminuria, it continued in the two
untreated patients, whereas regression oc-
curred in almost all treated patients
(6/7treated).Inthesecases,theregression
was probably due to long-lasting ACE in-
hibitor therapy, which had to be contin-
ued for several years (mean 9 years) to be
effective. We should not forget that ap-
proximately 30 years ago, dealing with
similar patients, Viberti et al. (1) reported
“proteinuria of this degree ($0.5 g/24 h)
is the earliest indicator of a progressive
and relentless decline of glomerular func-
tion leading a few years later to end-stage
renal failure.” The macroalbuminuria
regressed in our patients, but once regres-
sion was reached, it remained stable with-
out relapse for a mean period of 9 years,
even after therapy withdrawal in two pa-
tients. We are aware that the number of
patients is too low to be able to draw def-
inite conclusions, but, if conﬁrmed, this
should be considered clinically remark-
able. However, we cannot be certain that
the regression to normoalbuminuria cor-
respondstoanormalizationofrenalstruc-
ture, as already hypothesized by others
(6,20). In fact, the progressive decrease
of estimated GFR found in our treated pa-
t i e n tw i t ha b n o r m a lU A E ,w h i c hi m -
proved from macroalbuminuria to a mild
MA, seems consistent with that hypothe-
sis. We cannot exclude that the treatment
wasstartedtoolatetostoptheprogression
ofrenaldiseaseinthispatient.Fewstudies
are available in the literature on children
and adolescents with macroalbuminuria
(14), and no comparable data exist for
children with a similar follow-up. Several
studies agree in conferring on glycemic
control a determinant role in abnormal
UAE progression (4,7,8). Our ﬁndings
areconsistentwiththesedata.Normalized
patients had signiﬁcantly lower HbA1c
levels than patients with persistently ab-
normal UAE. A further modiﬁable factor,
recently identiﬁed as a predictor of renal
disease progression, is the lipid proﬁle
(19,21), which, according to some au-
thors, has a pathogenic role in progressive
glomerular injury (7). On the other hand,
patients with type 1 diabetes and ne-
phropathy have a 10-fold greater risk of
cardiovascular diseases than those with-
out nephropathy (8,22), and multiple
lipid abnormalities, such as higher total
cholesterol, LDL cholesterol (19,21), and
triglycerides (7), and lower HDL choles-
terol levels (21,23), have been described.
We found some of these abnormalities in
patients with abnormal UAE: higher LDL
cholesterol in the whole group versus
control group and lower triglycerides in
the normalized versus non-normalized
Table 2—Lipid proﬁle in microalbuminuric patients in the whole group and in subgroups subdivided according to remission or enalapril
treatment (values referred to ﬁrst abnormal UAE detection)
All microalbuminuric
patients (n =4 1 )
Normoalbuminuric
patients (n =1 3 4 )
Persistent
(n =8 )
Normalized
(n = 33)
Pre-therapy
(n =2 1 )
Post-therapy
(n =2 1 ) °
Triglycerides (mg/dL) 76.9 6 37.7 73.8 6 39.4 102.8 6 47.2 71.6 6 34.0* 80.8 6 45.4 85.4 6 35.3
Total cholesterol (mg/dL) 171.7 6 32.9 166.7 6 31.1 168.0 6 32.0 172.4 6 33.6 179.7 6 34.6 180.8 6 28.1
LDL cholesterol (mg/dL) 104.1 6 30.2† 88.2 6 23.9 128.0 6 44.5 99.1 6 24.6 106.8 6 27.6 107.9 6 26.6
HDL cholesterol (mg/dL) 51.0 6 11.4‡ 62.4 6 13.6 42.7 6 8.6 52.7 6 11.3* 49.3 6 10.9§ 58.6 6 10.0
°Paired t test. *P , 0.05; †P , 0.005; ‡P , 0.0001; §P , 0.001 vs. the respective group.
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lipids may not be reliable, because they
are secondary to worse glycemic control
(19). In conﬁrmation of the data by
Molitch et al. (23) in adult diabetic pa-
tients with albuminuria, the most signiﬁ-
cant and persistent abnormality found in
our study was the presence of lower HDL
cholesterollevelsinthemicroalbuminuric
patients, found in the whole group versus
normoalbuminuric patients, in normal-
ized versus non-normalized patients, and
ﬁnally post- versus pre-ACE inhibition
(Table 2). This ﬁnding is not surprising,
becauseHDLcholesterol,unrelatedtogly-
cemic control (19) and the remaining lip-
ids, is basically constant over time and
moreclosely represents thegeneticallyde-
termined part of a certain patient. This is
supported by sibling-pair studies of can-
didate genes (24). The central role of HDL
cholesterol in characterizing the diabetic
patients with long-term good prognosis
also was conﬁrmed by the Golden Years
Cohort (type 1 diabetes of .50 years du-
ration), and the authors who reported
these data concluded that the high HDL
levels could be used as an early clinical
marker of good prognosis in type 1 diabe-
tes (9) and that “these features can be tied
together in terms of the antithesis of the
metabolic syndrome X.” Other studies
have reported no signiﬁcant changes in
HDL cholesterol, but this could have
been because this parameter was mea-
sured at different times. In fact, HDL cho-
lesterol in our study was measured at the
ﬁrstdetectionofabnormalUAE,atamuch
younger age, when the confounding fac-
tors such as antihypertensive therapy or
the complication itself did not interfere
with the basal lipid proﬁle of the patient.
We have no explanation for the enalapril
effect, not only on MA but also on HDL
cholesterol, which was the only lipid to be
inﬂuenced by the treatment. The effect on
HDL cholesterol is more difﬁcult to
explain because it was found in both nor-
malized and persistent micro-macroalbu-
minuric patients. In the latter patients,
UAE values tended to decrease during
treatment; thus, the lack of complete
regressionmaysimplybeduetotime.Fur-
thermore, it is known that the antiprotei-
nuric effect of ACE inhibitors cannot
entirely be explained by changes in blood
pressure (6).
Our study has some limitations. The
small sample size, the nonstandardized
criteria of randomized controlled trials in
the choice of patients to be treated, the
method of collecting urine samples, and
the variable duration of follow-up may
limit the precision of our ﬁndings. Other
factors, including genetic factors, should
be examined. Finally, high HDL choles-
terol values may be associated with high
levels of physical activity and excessive
alcohol intake, but none of our patients,
subsequently interviewed on the subject,
reported these situations.
Insummary,ourﬁndingssuggestthat
if abnormal and nocturnal elevated UAE
does not spontaneously decrease in 1–2
years in diabetic children and adoles-
cents, ACE inhibition should be used.
Its long-lasting use also seemed effective
in our small cohort of patients with mac-
roalbuminuria, especially when associ-
ated with better glycemic control and
higher HDL cholesterol levels. This
provides a rationale for future studies on
administration of products able to di-
rectly increase HDL cholesterol, such as
n-3 fatty acids (25), before MA onset in
patients at risk, that is, those with low
HDL cholesterol.
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